A Message from the Chairs of NRG Oncology’s Research Strategy Committee

01/17/2024

We
are happy to report that the Protocol Development Department
coordinated the activation of 8 studies in 2023, two of which are part
of the NCI ComboMATCH Treatment Trial (

See table). The
exciting news is that we have another 13 NCI approved concepts along
with 1 NCI ComboMATCH study that are in protocol development with
activations anticipated in 2024/2025. There were also 16 other concepts
that were approved for future development during our Research Strategy
Meetings held this past year. We are thankful to have a robust and
diverse clinical trial portfolio and are excited about the new trial
concepts we continue to receive from our dedicated committees and
investigators.

On
behalf of NRG Oncology’s Research Strategy Committee’s leadership, we
want to thank our committee leaders and members, our study chairs, and
our amazing staff for all their hard work and resulting success this
past year. We look forward to an even better 2024!

Ronald D. Alvarez, MD        Jame Abraham, MD